Literature DB >> 23782387

Early arterial stasis during resin-based yttrium-90 radioembolization: incidence and preliminary outcomes.

Peachy Mae Piana1, Voichita Bar, Laura Doyle, Rani Anne, Takami Sato, David J Eschelman, Jeffrey W McCann, Carin F Gonsalves, Daniel B Brown.   

Abstract

OBJECTIVES: This study was conducted to determine the incidence of early stasis in radioembolization using resin yttrium-90 (Y-90) microspheres, to evaluate potential contributing factors, and to review initial imaging outcomes.
METHODS: Patients in whom early stasis occurred were compared with those in whom complete delivery was achieved for tumour type and vascularity, tumour : normal liver ratio (T : N ratio) at technetium-99m-macroaggregated albumin (Tc-99m-MAA) angiography, previous intra-arterial therapy, and infusion site (left, right or whole liver). Tumour response was evaluated at 3 months and defined according to whether a partial response and stable disease versus progressive disease were demonstrated.
RESULTS: A total of 71 patients underwent 128 Y-90 infusions in which 26 (20.3%) stasis events occurred. Hypervascular and hypovascular tumours had similar rates of stasis (17.4% versus 27.8%; P = NS). The mean ± standard deviation T : N ratio was 3.03 ± 1.54 and 3.66 ± 2.79 in patients with and without stasis, respectively (P = NS). Stasis occurred in 14 of 81 (17.3%) and 12 of 47 (25.5%) infusions following previous intra-arterial therapy and in therapy-naïve territories, respectively (P = NS). Early stasis occurred in 15 of 41 (36.6%) left, 10 of 65 (15.4%) right and one of 22 (4.5%) whole liver infusions (P < 0.001). Rates of partial response and stable disease were similar in the stasis (88.3%) and non-stasis (76.0%) groups (P = NS).
CONCLUSIONS: Early stasis occurred in approximately 20% of infusions with similar incidences in hyper- and hypovascular tumours. Whole-liver therapy reduced the incidence of stasis. Stasis did not appear to affect initial imaging outcomes.
© 2013 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23782387      PMCID: PMC3967885          DOI: 10.1111/hpb.12135

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  25 in total

1.  Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases.

Authors:  Mehdi Karoui; Christophe Penna; Mohamed Amin-Hashem; Emmanuel Mitry; Stephane Benoist; Brigitte Franc; Philippe Rougier; Bernard Nordlinger
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

2.  Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization.

Authors:  Kent Sato; Robert J Lewandowski; James T Bui; Reed Omary; Russell D Hunter; Laura Kulik; Mary Mulcahy; David Liu; Howard Chrisman; Scott Resnick; Albert A Nemcek; Robert Vogelzang; Riad Salem
Journal:  Cardiovasc Intervent Radiol       Date:  2006 Jul-Aug       Impact factor: 2.740

3.  Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer.

Authors:  B Gray; G Van Hazel; M Hope; M Burton; P Moroz; J Anderson; V Gebski
Journal:  Ann Oncol       Date:  2001-12       Impact factor: 32.976

4.  Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases.

Authors:  Jean-Nicolas Vauthey; Timothy M Pawlik; Dario Ribero; Tsung-Teh Wu; Daria Zorzi; Paulo M Hoff; Henry Q Xiong; Cathy Eng; Gregory Y Lauwers; Mari Mino-Kenudson; Mauro Risio; Andrea Muratore; Lorenzo Capussotti; Steven A Curley; Eddie K Abdalla
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

5.  Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results.

Authors:  Ravi Murthy; Henry Xiong; Rodolfo Nunez; Alan C Cohen; Bruce Barron; Janio Szklaruk; David C Madoff; Sanjay Gupta; Michael J Wallace; Kamran Ahrar; Marshall E Hicks
Journal:  J Vasc Interv Radiol       Date:  2005-07       Impact factor: 3.464

6.  Toxicities after radioembolization with yttrium-90 SIR-spheres: incidence and contributing risk factors at a single center.

Authors:  Peachy Mae Piana; Carin F Gonsalves; Takami Sato; P Rani Anne; Jeffrey W McCann; Voichita Bar Ad; David J Eschelman; Laurence Parker; Laura A Doyle; Daniel B Brown
Journal:  J Vasc Interv Radiol       Date:  2011-07-20       Impact factor: 3.464

7.  Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET.

Authors:  Frank H Miller; Ana L Keppke; Denise Reddy; Jie Huang; Jianhua Jin; Mary F Mulcahy; Riad Salem
Journal:  AJR Am J Roentgenol       Date:  2007-03       Impact factor: 3.959

8.  Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres.

Authors:  Ana L Keppke; Riad Salem; Denise Reddy; Jie Huang; Jianhua Jin; Andrew C Larson; Frank H Miller
Journal:  AJR Am J Roentgenol       Date:  2007-03       Impact factor: 3.959

9.  Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium.

Authors:  Andrew Kennedy; Subir Nag; Riad Salem; Ravi Murthy; Alexander J McEwan; Charles Nutting; Al Benson; Joseph Espat; Jose Ignacio Bilbao; Ricky A Sharma; James P Thomas; Douglas Coldwell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-05-01       Impact factor: 7.038

10.  Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy.

Authors:  Ravi Murthy; Daniel B Brown; Riad Salem; Steven G Meranze; Douglas M Coldwell; Sunil Krishnan; Rodolfo Nunez; Amit Habbu; David Liu; William Ross; Alan M Cohen; Michael Censullo
Journal:  J Vasc Interv Radiol       Date:  2007-04       Impact factor: 3.464

View more
  16 in total

Review 1.  Bland Liver Tumor Embolization Complicated by Hepatic Abscess.

Authors:  Omar H Elsayed-Ali; Andrew J Lipnik; Daniel B Brown
Journal:  Semin Intervent Radiol       Date:  2015-09       Impact factor: 1.513

2.  Five percent dextrose maximizes dose delivery of Yttrium-90 resin microspheres and reduces rates of premature stasis compared to sterile water.

Authors:  Mary Ellen Koran; Samantha Stewart; Jennifer C Baker; Andrew J Lipnik; Fil Banovac; Reed A Omary; Daniel B Brown
Journal:  Biomed Rep       Date:  2016-11-01

3.  Quantitative Imaging Biomarkers for 90Y Distribution on Bremsstrahlung SPECT After Resin-Based Radioembolization.

Authors:  Isabel Schobert; Julius Chapiro; Nariman Nezami; Charlie A Hamm; Bernhard Gebauer; MingDe Lin; Jeffrey Pollak; Lawrence Saperstein; Todd Schlachter; Lynn J Savic
Journal:  J Nucl Med       Date:  2019-01-17       Impact factor: 10.057

Review 4.  Transarterial Radioembolization Agents: a Review of the Radionuclide Agents and the Carriers.

Authors:  Aysheh Alrfooh; Aditi Patel; Sandeep Laroia
Journal:  Nucl Med Mol Imaging       Date:  2021-07-13

Review 5.  Radioembolization of Colorectal Liver Metastases: Indications, Technique, and Outcomes.

Authors:  F Edward Boas; Lisa Bodei; Constantinos T Sofocleous
Journal:  J Nucl Med       Date:  2017-09       Impact factor: 10.057

6.  90Y Resin Microspheres Radioembolization for Colon Cancer Liver Metastases Using Full-Strength Contrast Material.

Authors:  I Kurilova; R G H Beets-Tan; G A Ulaner; F E Boas; E N Petre; H Yarmohammadi; E Ziv; A R Deipolyi; L A Brody; M Gonen; Constantinos T Sofocleous
Journal:  Cardiovasc Intervent Radiol       Date:  2018-05-15       Impact factor: 2.740

7.  Incidence and risk factors of early arterial blood flow stasis during first radioembolization of primary and secondary liver malignancy using resin microspheres: an initial single-center analysis.

Authors:  Claus Christian Pieper; Winfried A Willinek; Daniel Thomas; Hojjat Ahmadzadehfar; Markus Essler; Jennifer Nadal; Kai E Wilhelm; Hans Heinz Schild; Carsten Meyer
Journal:  Eur Radiol       Date:  2015-11-11       Impact factor: 5.315

Review 8.  Radioembolization for the Treatment of Primary and Metastatic Liver Cancers.

Authors:  Eun Jeong Lee; Hyun Woo Chung; Joon-Hyung Jo; Young So
Journal:  Nucl Med Mol Imaging       Date:  2019-11-08

9.  Radioembolization With Holmium-166 Polylactic Acid Microspheres: Distribution of Residual Activity in the Delivery Set and Outflow Dynamics During Planning and Treatment Procedures.

Authors:  Robert Drescher; Philipp Seifert; Falk Gühne; René Aschenbach; Christian Kühnel; Martin Freesmeyer
Journal:  J Endovasc Ther       Date:  2021-02-25       Impact factor: 3.487

Review 10.  Microspheres Used in Liver Radioembolization: From Conception to Clinical Effects.

Authors:  Philippe d'Abadie; Michel Hesse; Amandine Louppe; Renaud Lhommel; Stephan Walrand; Francois Jamar
Journal:  Molecules       Date:  2021-06-29       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.